Preparation of Oligosaccharides
By introducing glycosyltransferase and sucrose utilization system into E. coli cells, the problem of microorganisms survival and growth on sucrose is solved, and a method for efficient preparation of recombinant oligosaccharides, especially HMO, is realized, which improves production efficiency and economicality.
Patent Information
- Application Number
- CN202111067517.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2015-06-29
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2035-06-29
AI Technical Summary
Existing recombinant microorganisms are difficult to survive and grow on sucrose, limiting their application as a carbon source and energy source in industry, especially in the manufacturing of recombinant oligosaccharides such as HMO.
By introducing recombinant genes encoding glycosyltransferases and sucrose utilization systems in E. coli cells, especially heterologous PTS-dependent sucrose utilization systems, allows cells to use sucrose as a carbon source and energy source to perform glycosylation reactions for synthesis Oligosaccharide.
Transformed microorganisms that survive and grow efficiently on sucrose can be effectively prepared, especially HMO, and improve production efficiency and economicality.
Smart Images

Figure CN113684233B_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with the invention name “Preparation of Oligosaccharides” and application number “201580034968.9” filed on June 29, 2015. Technical Field
[0002] The present invention relates to the field of biotechnology, in particular to the microbial preparation of recombinant oligosaccharides, in particular human milk oligosaccharides (HMO), using transgenic microorganisms, in particular Escherichia coli (E. coli), and sucrose as its exclusive carbon source. Background Art
[0003] Recently, fermentative synthesis of foreign or exogenous oligosaccharides using recombinant microorganisms has become of great commercial and industrial interest. In such synthesis, the oligosaccharide of interest will be synthesized by enzymatic glycosylation of a sugar acceptor mediated by one or more heterologous glycosyltransferases of the microorganism, and one or more activated sugar nucleotides required for glycosylation will be prepared by the same microorganism by overexpressing one or more genes encoding endogenous activated sugar nucleotide producing enzymes. The metabolic pathway for this synthesis requires a carbon source, which is mainly a simple carbon building block, usually glycerol or glucose (see, for example, WO01 / 04341, Priem et al. Glycobiology 12, 235 (2002), Fort et al. Chem. Comm. 2558 (2005), Drouillard et al. Angew. Chem. Int. Ed. 45, 1778 (2006), WO2010 / 070104, WO2012 / 112777, WO2013 / 182206, WO2014 / 048439). In some syntheses, if lactose is also used as an acceptor, it can be a carbon source (Lee et al. Microb. Cell Fact. 11: 48 (2012)). Since the microorganisms have been genetically manipulated, antibiotic resistance selection marker genes have been used to separate the transformed microorganisms from the untransformed microorganisms in the inoculum and fermentation broth. However, the use of antibiotics has been circumvented by integrating genes encoding enzymes involved in the de novo biosynthesis of donor sugars into the chromosome of the microorganism ( et al. Microb. Cell Fact. 12: 40 (2013)).
[0004] About 50% of wild-type E. coli can use sucrose as a carbon and energy source, but most of them are pathogenic. E. coli strains mainly used in the synthesis of chemicals in industry cannot survive and grow on sucrose (Bruschi et al., Biotechnol. Adv. 30, 1001 (2012)). However, in some cases, sucrose can be a cheaper carbon and energy source. For this reason, attempts have been made to develop sucrose strains of E. coli that can survive and grow on sucrose. + strains (e.g., Sabri et al., Appl. Environ. Microbiol 79, 478 (2013)) and by them to produce industrially profitable products, such as amino acids, biofuels, carotenoids, etc. (e.g., EP-A-1149911, EP-A-2239336, EP-A-2371952, EP-A-2405006, WO2010 / 051849, WO2012 / 078311, Kim et al., Biores. Technol. 130, 288 (2013)). However, these suc + Transformants usually have no suc — The strain is prolific (Khamduang et al. J. Ind. Microbiol. Biotechnol. 36, 1267 (2009)).
[0005] WO2012 / 007481 describes an E. coli transformant expressing sucrose phosphorylase or sucrose invertase in combination with fructokinase. Thus, the microorganism is able to produce 2'-fucosyllactose using sucrose as its main carbon source. Moreover, WO2014 / 067696 describes an E. coli transformant containing a csc gene cluster enabling it to grow on sucrose and produce fucose.
[0006] However, there continues to be a need for alternative methods for producing recombinant oligosaccharides, particularly HMOs, using transformed microorganisms that are able to utilize more efficient sucrose as a carbon and energy source. Summary of the invention
[0007] A first aspect of the present invention relates to a method for preparing a recombinant oligosaccharide, preferably a recombinant oligosaccharide of 3 to 8 monosaccharide units, more preferably a recombinant oligosaccharide of 3 to 5 monosaccharide units, in particular a HMO, by glycosylation of a carbohydrate acceptor, wherein the carbohydrate acceptor is preferably lactose and not sucrose, the method comprising the following steps:
[0008] a) providing a cell, preferably an E. coli cell, which is capable of internalizing the receptor into the cell and which comprises
[0009] - a recombinant gene encoding a glycosyltransferase capable of transferring a sugar residue of an activated sugar nucleotide to a receptor internalized in said cell, and
[0010] - a biosynthetic pathway for producing said activated sugar nucleotide in said cell,
[0011] b) culturing the cell in the presence of the receptor and sucrose, and
[0012] c) isolating the oligosaccharide from the cell, the culture medium or both,
[0013] The method is characterized in that the cell further comprises one or more genes encoding a sucrose utilization system, preferably encoding a heterologous sucrose utilization system, more preferably encoding a heterologous PTS-dependent sucrose utilization transport system, more preferably a scr gene, whereby the cell is able to use sucrose as a carbon source, preferably as the main carbon source, more preferably as the sole carbon source, for producing the activated sugar nucleotides, and as an energy source, preferably as the main energy source, more preferably as the sole energy source, for producing the oligosaccharides.
[0014] A second aspect of the invention relates to a cell, preferably an E. coli cell, capable of internalizing a carbohydrate acceptor into the cell, preferably lactose, and not sucrose, the method comprising:
[0015] - a recombinant gene encoding a glycosyltransferase capable of transferring a sugar residue of an activated sugar nucleotide to a receptor internalized in said cell,
[0016] - a biosynthetic pathway for producing said activated sugar nucleotide in said cell, and
[0017] - one or more genes encoding a sucrose utilization system, preferably encoding a heterologous sucrose utilization system, more preferably a scr gene, whereby the cell is able to use sucrose as a carbon source, preferably as the main carbon source, more preferably as the sole carbon source. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 It is intended to further illustrate the invention but is not intended to limit the subject matter of the invention.
[0019] The modified microorganism is a fully metabolically active cell in which growth and oligosaccharide synthesis can be carried out simultaneously. The cell contains a heterologous PTS-dependent sucrose utilization transport system, which includes a sucrose-specific porin (promoting the diffusion of sucrose through the outer membrane), a sucrose transporter (providing intracellular sucrose-6-phosphate from extracellular sucrose) and a sucrose-6-phosphate hydrolase (providing glucose-6-phosphate and fructose). Through the organism's own metabolic system, the oxidation of glucose-6-phosphate and fructose provides a biological energy source. In addition, glucose-6-phosphate and fructose are used as carbon sources for preparing sugar nucleotides in the natural biosynthetic pathway of the cell. The sugar nucleotides prepared in this way are donors for glycosylation of carbohydrate acceptors (e.g., lactose) internalized by the cell through specific permeases, thereby preparing the target oligosaccharides. Glycosylation is mediated by one or more glycosyltransferases, which are directly prepared by expressing heterologous genes. The organism lacks any enzyme that degrades the acceptors or oligosaccharide products in the cell. DETAILED DESCRIPTION
[0020] Surprisingly, it has been found that exogenous mono- or disaccharide acceptors, preferably lactose, can be internalized in suitable transgenic microorganisms, particularly Escherichia coli, by a transport mechanism involving microbial permeases, in which carbohydrate acceptors can be glycosylated using sucrose as their carbon and energy source, and exogenous oligosaccharides can be prepared and isolated in good yields. Thus, an efficient, inexpensive and easily scalable method for preparing oligosaccharides can be obtained. In order for this method to be successful, special oligosaccharide-preparing microorganisms are required that can survive on sucrose, utilize sucrose for the metabolic synthesis of nucleotide sugar donors necessary for glycosylation, and can internalize simple carbohydrate acceptors and glycosylate them to synthesize more complex oligosaccharides.
[0021] Therefore, the first aspect of the present invention relates to a method for producing oligosaccharides by the following steps:
[0022] a) providing a microbial cell, preferably an E. coli cell, which is capable of internalizing sucrose and a carbohydrate acceptor, preferably lactose, into the cell and which comprises:
[0023] - a recombinant gene encoding a glycosyltransferase capable of transferring the sugar residue of an activated sugar nucleotide to an acceptor in the cell, and
[0024] - a biosynthetic pathway for producing activated sugar nucleotides from sucrose,
[0025] b) culturing the cells in an aqueous medium in the presence of an acceptor and sucrose, and
[0026] c) isolating the oligosaccharide product from the cells, from the culture medium, or from both.
[0027] The method is characterized in that the cell is transformed with one or more heterologous genes encoding a sucrose utilization system, which allows the cell to use sucrose as a carbon source, preferably as the main carbon source, more preferably as the sole carbon source, for the biosynthesis of activated sugar nucleotides by the cell. The sucrose utilization system with which the cell is transformed also preferably allows the cell to use sucrose as an energy source, preferably as the main energy source, more preferably as the sole energy source, for the biosynthesis of oligosaccharides.
[0028] According to the present invention, the term "carbohydrate acceptor" or "acceptor" preferably refers to a monosaccharide or disaccharide other than sucrose and its glycosides. The monosaccharide part of the monosaccharide acceptor or disaccharide acceptor includes any sugar part of 5 to 6 carbon atoms, which is an aldose (e.g., D-glucose, D-galactose, D-mannose, D-ribose, D-arabinose, L-arabinose, D-xylose, etc.), a ketose (e.g., D-fructose, D-sorbose, D-tagatose, etc.), a deoxy sugar (e.g., L-rhamnose, L-fucose, etc.) or a deoxy amino sugar (e.g., N-acetylglucosamine, N-acetylmannosamine, N-acetylgalactosamine, etc.). In glycosidic carbohydrate acceptors, the sugar moiety is linked to a non-sugar residue (aglycone) by a covalent bond or linker, wherein the covalent bond is a direct link between the glycosidic carbon atom of the sugar residue and any atom of the non-sugar moiety, wherein the linker is composed of one, two, three or four of the following atoms: -O-, -C-, -NH-, -N(OH)-, -S-, -C(=O)-, -C(=S)-, -C(=NH)-, -C(=N-OH) -, -C(=O)-O-, -OC(=O)-, -C(=O)-S-, -SC(=O)-, -C(=S)-O-, -OC(=S)-, -C(=S)-S-, -SC(=S)-, -C(=O)-NH-, -NH-C(=O)-, -C(=NH)-O-, -OC(=NH)-, -C(=S)-NH-, -NH-C(=S)-, -C(=NH)-S- and -SC(=NH)-. Thus, the C-1 (in the case of aldose) or C-2 (in the case of ketose) anomeric carbon atom at the reducing end of the monosaccharide or disaccharide residue is linked to the non-sugar moiety by a covalent bond or a linking bond forming an O-, N-, S- or C-glycoside. Preferably, the aglycone of these glycoside derivatives with or without a linking bond is one of the following groups:
[0029] a)-OR A , where R Ais a straight or branched hydrocarbon chain having 1 to 24, preferably 1 to 6, carbon atoms when saturated (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-hexyl, etc.), or 2 to 24, preferably 2 to 6, carbon atoms when unsaturated (e.g., vinyl, allyl, propargyl, etc.), or R A represents an aryl moiety (same as an aromatic group such as phenyl or naphthyl), or R A represents a group that can be removed by hydrogenolysis, i.e., a group bonded to oxygen that can be cleaved off by hydrogen addition in the presence of a catalytic amount of palladium, Raney nickel or other metal catalyst known to be suitable for hydrogenolysis, resulting in regeneration of the OH group; such protecting groups are known to those skilled in the art and are discussed in Protective Groups in Organic Synthesis, PGM Wuts and TW Greene, John Wiley & Sons 2007. Suitable groups include benzyl, diphenylmethyl (diphenylmethyl), 1-naphthylmethyl, 2-naphthylmethyl or triphenylmethyl (trityl) groups. Any of the above R A The group may be optionally substituted by one or more of the following groups: alkyl (only for aryl and groups removable by hydrogenolysis), hydroxy, alkoxy, carboxy, oxo, alkoxycarbonyl, alkylcarbonyl, formyl, aryl, aryloxycarbonyl, aryloxy, arylamino, arylcarbonyl, amino, mono- and dialkylamino, carbamoyl, mono- and dialkylaminocarbonyl, alkylcarbonylamino, cyano, alkanoyloxy, nitro, alkylthio and halogen; in the case of groups removable by hydrogenolysis, if such substitution is present, it is preferably on the aromatic ring;
[0030] b) -XR B , where X is N or S, and R B represents a straight or branched hydrocarbon chain, which, when saturated, has 1 to 24, preferably 1 to 6 carbon atoms (such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-hexyl, etc.), or, when unsaturated, has 2 to 24, preferably 2 to 6 carbon atoms (such as vinyl, allyl, propargyl, etc.). or R B represents an aryl moiety (same as an aromatic group such as phenyl or naphthyl), or R B represents a benzyl group. BThe group may be optionally substituted with one or more selected from the group consisting of alkyl (for aryl and benzyl only), hydroxy, alkoxy, carboxy, oxo, alkoxycarbonyl, alkylcarbonyl, formyl, aryl, aryloxycarbonyl, aryloxy, arylamino, arylcarbonyl, amino, mono- and dialkylamino, carbamoyl, mono- or dialkylaminocarbonyl, alkylcarbonylamino, cyano, alkanoyloxy, nitro, alkylthio, and halogen;
[0031] c) A group connecting the anomeric carbon atom and the adjacent carbon atom to each other via a -NH-C(=O)-O- bridge, thereby forming a fused five-membered ring as shown in the case of aldose:
[0032]
[0033] d) azide;
[0034] e) -NH-C(R")=C(R')2, wherein each R' independently represents an electron withdrawing group selected from -CN, -COOH, -COO-alkyl, -CO-alkyl, -CONH2, -CONH-alkyl and -CON(alkyl)2, or wherein two R' groups are linked together to form -CO-(CH2) 2-4 -CO-, and thus the carbon atom to which it is attached forms a 5- to 7-membered cycloalkyl-1,3-dione, any methylene group in the dione is optionally substituted by 1 or 2 alkyl groups, and wherein R" is H or alkyl;
[0035] f) an amino acid residue, which is any natural or non-natural amino acid, i.e. an alkanoic acid derivative having at least one amino group as a substituent. Preferably, the amino acid is selected from α-amino acids and β-amino acids such as Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val, hydroxyproline, α-methylserine, β-alanine, etc. These amino acids can be directly or via a linker as described above (e.g., for urea-linked glycopeptides, see WO 2009 / 040363) connected to the C-1 (in the case of aldose) or C-2 (in the case of ketose) anomeric carbon atom of the carbohydrate to form O-, N-, S- or C-glycosides. O-glycosides (O-polysaccharides) can be formed by involving OH-containing amino acids such as serine, threonine, hydroxyproline, etc., N-glycosides (N-polysaccharides) can be made with the α-, β-, etc. amino groups of any amino acid or with additional amino groups of the side chains of, for example, lysine, asparagine or glutamine, S-glycosides can be made with cysteine, and C-glycosides (C-polysaccharides) contain a C-C bond coupling the C atom of the amino acid to the anomeric carbon atom of the non-reducing end of the oligosaccharide moiety;
[0036] g) Polyethylene glycol residue. Polyethylene glycol (PEG) is a molecule with the formula C 2n H 4n+2 O n+1 A water-soluble polyether having repeating units of ethylene oxide (-CH2-O-CH2- or CH2-CH2-O-), wherein n is 2 to 100, preferably 2 to 50, particularly 2 to 25, and more particularly 2 to 10. Lower molecular weight PEGs can be used in purified form, referred to as "monodisperse PEGs", or as mixtures of PEGs, referred to as "polydisperse PEGs". In terms of their geometry, PEGs can be linear, branched, star-shaped or comb-shaped. Linear PEGs are preferably lower molecular weight PEGs (i.e., n is 2 to 10, preferably 3 to 6). Branched PEGs preferably have 3 to 10 linear, preferably low molecular weight PEG chains emanating from a central core group. Star-shaped PEGs preferably have 10 to 100 linear or branched, preferably low molecular weight PEG chains emanating from a central core group. Comb-shaped PEGs have multiple linear, branched and / or star-shaped, preferably low molecular weight PEG chains attached to a polymer backbone. The terminal primary hydroxyl groups of PEG can be connected to alkyl groups, preferably methyl groups, through ether bonds. In addition, their terminal hydroxyl groups can be replaced by amino, alkylamino, dialkylamino, amide, sulfhydryl or alkylthio groups, or their terminal hydroxyl groups can be oxidized to carboxyl groups, which can be esterified or exist in the form of amides of ammonia or primary or secondary amines. The connection is a glycosidic bond;
[0037] h) Polyvinyl alcohol residue. Polyvinyl alcohol (PVA) has the molecular formula (C2H4O) x A water-soluble polymer with a monomer unit of -CH2-CH(OH)-. When attached to a carbohydrate, any OH-group can be glycosylated;
[0038] i) α,β-unsaturated amide group of formula A
[0039]
[0040] wherein Q1, Q2, Q3 and Q4 are independently H and C1-C6 alkyl, wherein the alkyl group may be optionally substituted by halogen, OH, nitro or phenyl groups. The residue of formula A is covalently linked to a sugar, preferably to the anomeric carbon atom of a carbohydrate in N-glycosidic form, via its N atom; or
[0041] j) α,β-unsaturated carbonyl group of formula B
[0042]
[0043] wherein Q1, Q2 and Q3 are as defined for the residues of formula A.
[0044] Preferably, the carbohydrate acceptor is a galactosyl disaccharide, in particular lactose.
[0045] Furthermore, according to the present invention, the term "oligosaccharide product" or "oligosaccharide" preferably refers to a glycosylated derivative of a carbohydrate acceptor as described above, wherein the sugar residue is linked to the carbohydrate part of the carbohydrate acceptor by an internal glycosidic bond. Preferably, the oligosaccharide product is an oligosaccharide of 3 to 8 monosaccharide units, in particular an oligosaccharide of 3 to 5 monosaccharide units. The oligosaccharide product of the present invention is a recombinant product, i.e., it is produced by a transgenic microorganism and is foreign or heterologous to the microorganism.
[0046] According to the present invention, the term "microorganism" or "cell" preferably refers to a microbial cell, in particular an E. coli cell, in which there is at least one substitution in its DNA sequence. The substitution may result in a change in the original properties of the wild-type cell, for example, due to the introduction of new genetic material, which encodes the expression of enzymes not in the wild-type cell, the transformed cell being able to perform additional chemical transformations, or due to the removal (knockout) of genes which make transformations such as degradation impossible. Transgenic cells can be prepared in a conventional manner by genetic engineering techniques well known to those skilled in the art.
[0047] The transgenic microorganism or cell used in the method of the present invention is selected from bacteria or yeast, preferably bacteria. The bacterium is preferably selected from the group consisting of Escherichia coli, Bacillus spp. (e.g. Bacillus subtilis), Campylobacter pylori, Helicobacter pylori, Agrobacterium tumefaciens, Staphylococcus aureus, Thermophilus aquaticus, Azorhizobium caulinodans, Rhizobium leguminosarum, Neisseria gonorrhoeae, Neisseria meningitis, Lactobacillus spp., Lactococcus spp., Enterococcus spp.), Bifidobacterium spp., Sporolactobacillus spp., Micromomospora spp., Micrococcus spp., Rhodococcus spp., and Pseudomonas, among which Escherichia coli is preferred.
[0048] The method of the present invention also involves transporting an exogenous carbohydrate receptor, preferably lactic acid, into a transgenic microorganism for glycosylation to prepare a foreign oligosaccharide of interest, preferably one that does not adversely affect the basic functions of the cell or destroy its integrity. In one embodiment, transport occurs by a passive mechanism, during which the exogenous receptor passively diffuses through the plasma membrane of the cell. The diffusion of the receptor into the microorganism is the effect of the difference in receptor concentration between the extracellular and intracellular spaces of the fermentation broth and the cell, whereby the receptor is transferred from a high concentration area to a low concentration area. In another embodiment, the receptor is internalized with the help of active transport. In this case, the transgenic microorganism comprises a transporter protein, a so-called permease, which acts as an enzyme, whereby the microorganism is able to allow exogenous substances to enter and concentrate them in the cytoplasm. In particular, lactose permease (LacY) specifically acts on galactose, simple galactosyl disaccharides such as lactose and its glycosides. The specificity of the sugar portion of the exogenous carbohydrate receptor to be internalized can be changed by mutating the microorganism by conventional recombinant DNA manipulation techniques. In a preferred embodiment, the internalization of exogenous lactose or its derivatives occurs via an active transport mechanism mediated by lactose permease. The transgenic microorganism preferably lacks any enzyme activity (such as LacZ) that may degrade the receptor. Similarly, the microorganism is unable to hydrolyze or degrade the oligosaccharide product.
[0049] Furthermore, the transgenic cells used in the methods of the invention comprise one or more exogenous or recombinant genes encoding one or more glycosyltransferases capable of transferring the sugar residue of an activated sugar nucleotide to an internalized acceptor. If the gene or its equivalent DNA sequence is recombinant, it can be introduced into the cell by conventional techniques, for example using an expression vector or by chromosomal integration. The source of the heterologous nucleic acid sequence can be any animal (including human) or plant, eukaryotic cells such as those from Saccharomyces cerevisae, Saccharomyces pombe, Candida albican or those from algae, prokaryotic cells such as those from Escherichia coli, Bacterioides fragilis, Photobacterium sp., Bacillus subtilis, Campylobacter pylori, Helicobacter pylori, Agrobacterium tumefaciens, Staphylococcus aureus, Thermophilus aquaticus, Azorhizobium caulinodans, Rhizobium leguminosarum, leguminosarum), Rhizobium meliloti, Neisseria gonorrhoeae and Neisseria meningitidis, or viruses. The glycosyltransferase or the enzyme expressed by the protein encoded by the gene or equivalent DNA sequence is preferably a glucosyltransferase, a galactosyltransferase, an N-acetylglucosaminyltransferase, an N-acetylgalactosamine transferase, a glucuronyltransferase, a xylosyltransferase, a mannosyltransferase, a fucosyltransferase, a sialyltransferase, and the like. In a preferred embodiment, the glycosyltransferase is selected from the group consisting of β-1,3-N-acetylglucosamine-transferase, β-1,6-N-acetylglucosamine-transferase, β-1,3-galactosyl-transferase, β-1,4-galactosyl-transferase, β-1,3-N-acetylgalactosamine-transferase, β-1,3-glucuronyl-transferase, α-2,3-sialyl-transferase, α-2,6-sialyl-transferase, α-2,8-sialyl-transferase, α-1,2-fucosyl-transferase, α-1,3-fucosyl-transferase and α-1,4-fucosyl-transferase.More preferably, the glycosyltransferase is selected from the group consisting of β-1,3-N-acetylglucosaminyltransferase, β-1,6-N-acetylglucosaminyltransferase, β-1,3-galactosyltransferase, β-1,4-galactosyltransferase, α-2,3-sialyltransferase, α-2,6-sialyltransferase, α-1,2-fucosyltransferase, α-1,3-fucosyltransferase and α-1,4-fucosyltransferase, which are from those enzymes involved in the construction of the HMO core structure and fucosylated and / or sialylated HMO and glycosyl derivatives thereof, wherein the aglycone is a moiety defined at the group of the above carbohydrate acceptor. Genes encoding the above transferases have been described in the literature.
[0050] In the glycosylation method mediated by glycosyltransferase of the present invention, activated sugar nucleotides are used as donors. Each activated sugar nucleotide generally includes a phosphorylated sugar residue connected to a nucleotide, and specific glycosyltransferases only accept specific sugar nucleotides. Therefore, preferably the following activated sugar nucleotides participate in the glycosyl transfer: UDP-Glc, UDP-Gal, UDP-GlcNAc, UDP-GalNAc, UDP-glucuronic acid, UDP-Xyl, GDP-Man, GDP-Fuc and CMP-sialic acid, particularly preferably those selected from UDP-Gal, UDP-GlcNAc, GDP-Fuc and CMP-sialic acid.
[0051] The transgenic microorganism used in the method of the present invention has a biosynthetic pathway leading to the above-mentioned activated sugar nucleotides, that is, it has one or more sets of genes, the genes encoding one or more enzymes responsible for synthesizing one or more activated sugar nucleotides, when the cells are cultured, for glycosylation in the reaction mediated by glycosyltransferases in the cells. The set of genes is either naturally present in the cells or introduced into the cells by means of recombinant DNA manipulation techniques. The activated sugar nucleotides prepared by the cells are produced under the action of enzymes participating in the biosynthetic pathway of each sugar nucleotide stepwise reaction sequence, which starts from a carbon source (for a review of monosaccharide metabolism, see, for example, Essentials of Glycobiology 2nd Edition by HH Freeze and AD Elbein (A. Varki et al., ed.), Cold Spring Harbour Laboratory Press (2009), Chapter 4 Glycosylation Precursors).
[0052] It should be emphasized that the preparation of activated sugar nucleotides by transgenic microorganisms via their own biosynthetic pathways is advantageous compared to in vitro forms of transfer glycosylation, since it avoids the use of very expensive exogenously added sugar nucleotide donors, since the donors are formed in situ by the cells and the phosphatidyl nucleoside leaving groups are recycled within the cells.
[0053] In addition, the microorganism used in the inventive method comprises a gene encoding a sucrose utilization system, that is, the cell has the ability to utilize sucrose catabolism as a carbon source and energy source. The system that enables the cell to utilize sucrose can be one commonly found in the gene pool of the cell, but is preferably a heterologous system (that is, derived from different organisms and transferred to host cells by conventional recombinant DNA manipulation techniques, preferably via an expression vector). Two sucrose catabolism systems can usually be used. According to the phosphoenolpyruvate (PEP)-dependent phosphotransferase system ("PTS"), sucrose is transported to the microorganism and accompanied by phosphorylation to produce intracellular sucrose-6-phosphate, which is hydrolyzed into glucose-6-phosphate and fructose, and then they participate in the cell center carbon metabolism. PTS can be encoded by scr or sac genes. According to a non-phosphotransferase-dependent system ("non-PTS"), extracellular sucrose enters the cell with the help of a proton symport system (sucrose permease), and after transport, it is hydrolyzed into glucose and fructose by an invertase, and then they are phosphorylated. In this regard, the csc regulon consists of genes encoding enzymes responsible for non-PTS sucrose utilization.
[0054] During the fermentation period of the inventive method, the sucrose that provides energy by glycolysis is used for growth, breeding and maintaining its structure to the microorganism feeding of oligosaccharides. In addition, the sucrose taken by the cell provides the precursor of the necessary activated sugar nucleotide for synthesizing the glycosylation process that occurs in the cell by sucrose catabolism. The internalized carbohydrate acceptor participates in the glycosylation reaction induced by glycosyltransferase, and the sugar residue of the activated nucleotide donor produced by the cell is wherein transferred so that the acceptor is glycosylated. Optionally, when the cell expresses more than one glycosyltransferase, additional glycosylation reaction can occur, resulting in the formation of target oligosaccharides. Of course, the cell preferably lacks any enzyme activity that may degrade the oligosaccharide derivatives produced in the cell.
[0055] In the preferred implementation of the method for preparing oligosaccharide products, the sucrose utilization system is heterologous. This is for industrially profitable conversions similar to oligosaccharide preparation, when microorganisms, preferably bacteria, more preferably Escherichia coli are the best strains, because such strains do not usually have the ability to utilize sucrose. Therefore, a suitable expression plasmid or via chromosomal integration should be used to introduce a sucrose uptake box in cells that cannot utilize sucrose, so that it can utilize sucrose. More preferably, the sucrose path gene includes a PTS-dependent sucrose utilization system, and in particular, the sucrose regulator is scr. The microorganism with scr gene is, for example, Salmonella ssp., Klebsiella pneumonia, Bacteroides fragilis, Vibrio alginolyticus.
[0056] The scr genes include the following: scrY, scrA, scrB and scrR. Gene scrA encodes sucrose transporter II Scr , which provides intracellular sucrose-6-phosphate from the extracellular sucrose and the accompanying phosphorylation through the cell membrane via active transport. The sucrose-specific ScrY membrane pore protein (encoded by scrY) promotes the diffusion of sucrose through the outer membrane. The ScrB invertase (encoded by scrB) decomposes the accumulated sucrose-6-phosphate into glucose-6-phosphate and fructose by hydrolysis. Optionally, the fructokinase ScrK (encoded by scrK) phosphorylates fructose into fructose-6-phosphate, but the presence of this enzyme is not critical, because fructose can be phosphorylated by other mechanisms possessed by the cell. The repressor protein ScrR (encoded by scrR) negatively controls the expression of the scrYAB gene, and ScrR is induced by sucrose or fructose. In the presence of glucose, the expression of the sucrose gene is suppressed.
[0057] In a preferred embodiment, heterologous scr genes are introduced into microorganisms using plasmids, more preferably via a two-plasmid system, one of which contains the scrA gene and the other contains the scrB gene. scrY, scrR and optional scrK genes can be carried by either plasmid.
[0058] Furthermore, preferably, in the method of the present invention, no antibiotics are added to the fermentation broth.
[0059] In the method of the present invention, the carbohydrate acceptor to be glycosylated by the microorganism is a monosaccharide or disaccharide selected from galactose, N-acetylglucosamine, galactosylated monosaccharides, N-acetyl-glucosaminylated monosaccharides and glycoside derivatives thereof as defined above. All these carbohydrate derivatives can be easily taken up by cells with LacY permease by active transport and accumulated in the cell before glycosylation (WO01 / 04341, Fort et al. Chem. Soc., Chem. Comm. 2558 (2005), EP-A-1911850, WO2013 / 182206, WO2014 / 048439). This is because the cell is able to transport these carbohydrate acceptors into the cell with its LacY permease, and the cell lacks any enzyme capable of degrading these acceptors, in particular LacZ. Preferably, the cell has a missing or insufficient lacA gene on the lac operon.
[0060] According to another preferred embodiment, in the microorganism, the lacI gene of the lac repressor is also deleted. In the absence of a functional repressor, no inducer is required to express LacY.
[0061] According to another preferred embodiment, the transgenic cells, in particular LacZ, are cultured in an aqueous medium at the following stage: - Y + E. coli cells:
[0062] (a) exponential cell growth phase ensured by sucrose; then
[0063] (b) Sucrose feeding phase with continuous addition ensuring limited cell growth.
[0064] In the feeding phase, the exogenous carbohydrate acceptor, preferably lactose, to be internalized and glycosylated in the cells can be added to the culture medium once, sequentially or continuously. In this second phase, the acceptor can be added as a pure solid / liquid or as a concentrated aqueous solution or suspension. The preparation of oligosaccharides occurs in this second phase and can last for 6-7 days. Preferably, the feeding phase is carried out under conditions that allow the preparation of high cell density cultures.
[0065] The method of the present invention is characterized in that it is not necessary to change the carbon source and / or energy source between the growth phase and the preparation phase of the microorganism.
[0066] Optionally, the method further comprises adding an inducer to the culture medium to induce the cells to express enzymes and / or proteins involved in receptor transport, and / or involved in receptor glycosylation for internalization, and / or involved in the biosynthesis of activated sugar nucleotide donors. The inducer is preferably isopropyl β-D-thiogalactoside (IPTG) and is added to the culture medium at the beginning of the feeding phase. However, if the cells are Lacl - If the phenotype is not good, there is no need to use inducers.
[0067] It is believed that the above-mentioned microorganisms are highly stable under the processing conditions of the present invention. Therefore, it is believed that these microorganisms can use sucrose as their carbon source and energy source, at least with glycerol and / or glucose as their carbon source and / or energy source, and produce oligosaccharides at the same production rate, and in a more reliable and reproducible manner. In this regard, one or more plasmids, preferably one or two plasmids, comprising the scr gene (required for microorganisms that utilize sucrose) plus one or more glycosyltransferase genes (required for microorganisms that produce exogenous oligosaccharides) are particularly stable during the fermentation period of the above-mentioned microorganisms for more than 4 days, preferably 5 to 7 days.
[0068] At the end of the second stage, the oligosaccharide product has accumulated in the cell of the microorganism and in the extracellular matrix.Preferably, the product is transported to the outer supernatant of the cell in a passive manner, that is, it can diffuse to the outside through the cell membrane.One or more sugars in the cell flow out of the transporter, i.e., the protein that promotes the sugar derivative to flow out from the cell to the supernatant, can promote this transshipment.This sugar outflow transporter can be an exogenous or endogenous existence, and under the condition of fermentation, can be overexpressed to enhance the output of the oligosaccharide derivative produced.Can be changed by cell mutation with conventional recombinant DNA operation technology means for the specificity of the sugar part of the product to be secreted.Preferably, oligosaccharides accumulate in the extracellular matrix.Or, oligosaccharides can be transported to the outer supernatant of the cell by destroying the cell wall in a conventional manner.
[0069] The oligosaccharide product may then be isolated from the aqueous medium in which it was produced by the cells in a conventional manner.
[0070] The first step of isolating the oligosaccharides from the culture medium preferably comprises isolating the oligosaccharides from the microorganism that produces it. This preferably comprises clarifying the culture medium to remove suspended particles and pollutants produced by culturing the genetically modified microorganism, particularly cells, cell components, insoluble metabolites and fragments produced by culturing the genetically modified microorganism. In this step, the aqueous culture medium containing the oligosaccharide product can be clarified in a conventional manner. Preferably, the culture medium is clarified by centrifugation and / or filtration.
[0071] The second step of separating oligosaccharides from the culture medium preferably comprises removing all proteins and peptides, amino acids, RNA and DNA and any endotoxin and glycolipid that may interfere with subsequent separation steps from the aqueous culture medium, preferably after it has been clarified. In this step, protein and relevant impurities can be removed from the culture medium in a conventional manner. Preferably, by ultrafiltration, tangential flow high efficiency filtration, tangential flow ultrafiltration, affinity chromatography, ion exchange chromatography, hydrophobic interaction chromatography and / or gel filtration (i.e. size exclusion chromatography), protein and relevant impurities are removed from the culture medium by chromatography, more particularly by ion exchange chromatography or hydrophobic interaction chromatography. Except size exclusion chromatography, protein and relevant impurities are retained by chromatographic medium or the membrane selected, and the oligosaccharide product is retained in the aqueous culture medium.
[0072] If desired, after the protein and related impurities have been removed from the culture medium, the oligosaccharide product in the aqueous culture medium can then be separated from the sugar-like byproducts and from the culture medium. This can be suitably accomplished by subjecting the culture medium to chromatography. In the case of a neutral oligosaccharide product, such separation can be carried out in a chromatographic separation column filled with a conventional acidic cation exchange resin. The acidic cation exchange resin can be in the form of a monovalent or divalent cation, and is preferably H + , K + 、Na + Mg 2+ or Ca 2+ In the form of Ca 2+ Chromatographic separation can be carried out in a conventional manner at a solution pH of 2 to 9. The eluent used in the chromatographic separation is preferably water, especially deionized water, but aqueous salt solutions can also be used. Alcohols, such as ethanol, and aqueous alcohol mixtures can also be used.
[0073] According to a preferred embodiment, the method of the invention for preparing an oligosaccharide, preferably an oligosaccharide having a lactose unit at the reducing end, or a glycoside thereof comprises the following steps:
[0074] (i) providing a transgenic cell, the cell comprising:
[0075] - a recombinant gene encoding a glycosyltransferase capable of transferring the sugar residue of an activated sugar nucleotide to internalized lactose or a glycoside thereof, and
[0076] - the biosynthetic pathway leading to activated sugar nucleotides,
[0077] (ii) culturing the transgenic cells in the presence of exogenous lactose or its glycoside and sucrose, thereby inducing
[0078] - internalization of exogenous lactose or its glycosides by the transgenic cells via an active transport mechanism, and
[0079] - forming an oligosaccharide or a glycoside thereof having a lactose unit at the reducing end from the internalized lactose or a glycoside thereof by glycosyl transfer mediated by a glycosyltransferase expressed by the cell,
[0080] (iii) isolating the oligosaccharide product from the cells, from the culture medium, or from both,
[0081] Characterized in that the cell also comprises a heterologous sucrose utilization system, preferably a PTS-dependent sucrose utilization system, in particular a PTS-dependent sucrose utilization system in which the sucrose regulator is scr, to provide sucrose as a carbon source for the biosynthesis of the activated sugar nucleotides by the cell.
[0082] The transgenic cells used in the preferred method may have more than one recombinant gene encoding more than one glycosyltransferase, which is capable of transferring the sugar residue of the activated sugar nucleotide to the internalized receptor molecule or the glycosylated receptor previously prepared by the same cell, whereby the internalized receptor forms an oligosaccharide product by multiple glycosyltransferases mediated by the multiple glycosyltransferases expressed by the cell. Therefore, the oligosaccharide product obtained may be glycosylated lactose or its glycoside. Glycosylated lactose is preferably N-acetyl-glucosaminylated, galactosylated, fucosylated and / or sialylated lactose. In order to prepare these derivatives, the cell comprises one or more recombinant genes encoding N-acetyl-glucosaminyltransferase, galactosyltransferase, sialyltransferase and / or fucosyltransferase, and also comprises a biosynthetic pathway leading to the corresponding activated sugar nucleotides, i.e., UDP-GlcNAc, UDP-Gal, GDP-Fuc and / or CMP-sialic acid.
[0083] More preferably, the oligosaccharide product obtained by the present method is characterized by Formula 1:
[0084]
[0085] wherein Y is OH or a non-aglycone as defined above, preferably OH,
[0086] R1 is fucosyl or H,
[0087] R2 is fucosyl or H,
[0088] R3 is selected from H, sialic acid, N-acetyl-lactosamino and lacto-N-biosyl groups, wherein the N-acetyl-lactosamino group may carry a sugar residue comprising one or more N-acetyl-lactosamino groups and / or one or more lacto-N-biosyl groups; each N-acetyl-lactosamino and lacto-N-biosyl group may be substituted by one or more sialic acid residues and / or fucose residues,
[0089] R4 is selected from H, sialic acid and N-acetyl-lactosamino groups, the N-acetyl-lactosamino groups being optionally substituted by sugar residues comprising one or more N-acetyl-lactosamino groups and / or one or more lacto-N-biosyl groups; each N-acetyl-lactosamino and lacto-N-biosyl group being capable of being substituted by one or more sialic acid residues and / or fucose residues,
[0090] The proviso is that at least one of the R1, R2, R3 and R4 groups is different from H.
[0091] Even more preferably, the compound of formula 1 prepared by the present process is characterized by formula 1a, 1b or 1c
[0092]
[0093] wherein Y, R1 and R2 are as defined above, preferably OH,
[0094] R 3a is an N-acetyl-lactosamine group, which is optionally substituted by a sugar residue comprising one N-acetyl-lactosamine group and / or one lacto-N-biosyl group; each of the N-acetyl-lactosamine group and the lacto-N-biosyl group may be substituted by one or more sialic acid residues and / or fucose residues,
[0095] R 4a is H or N-acetyl-lactosamine, which is optionally substituted by a lacto-N-biosyl group; each of the N-acetyl-lactosamine and lacto-N-biosyl groups may be substituted by one or more sialic acid residues and / or fucose residues,
[0096] R 3b is a lacto-N-biosyl group, which is optionally substituted by one or more sialic acid residues and / or fucose residues,
[0097] R 4b is H or N-acetyl-lactosamine, which is optionally substituted by one or two N-acetyl-lactosamine and / or one lacto-N-disaccharide group; each N-acetyl-lactosamine and lacto-N-disaccharide group may be substituted by one or more sialic acid residues and / or fucose residues,
[0098] R5 is independently H or sialic acid,
[0099] And wherein at least one of R1, R2 or R5 is not H.
[0100] Still more preferably, the compound according to formula 1a or 1b prepared by the present process is characterized in that:
[0101] -R 3a The N-acetyl-lactosamine group in the sugar residue is connected to another N-acetyl-lactosamine group having 1 to 3 internal glycosidic bonds,
[0102] -R 3a The lacto-N-biosyl group in the sugar residue is connected to the N-acetyl-lactosaminoglycan group having 1 to 3 internal glycosidic bonds,
[0103] -R 4a The lacto-N-biosyl group in the sugar residue is connected to an N-acetyl-lactosaminoglycan group having 1 to 3 internal glycosidic bonds,
[0104] -R 4b The N-acetyl-lactosamine group in the sugar residue is connected to the N-acetyl-lactosamine group having 1 to 3 or 1 to 6 internal glycosidic bonds,
[0105] -R 4b The lacto-N-biosyl group in the sugar residue is linked to the N-acetyl-lactosaminoglycan group with 1 to 3 internal glycosidic bonds.
[0106] More preferably, the compounds according to formula 1a, 1b and 1c prepared by the present method are human milk oligosaccharides (when Y is OH) or glycosides thereof (when Y is a non-aglycone).
[0107] The preferred compounds of formula 1a prepared by the present method are selected from lacto-N-neotetraose, p-lacto-N-hexaose, p-lacto-N-neohexose, lacto-N-neohexose, p-lacto-N-octaose, lacto-N-neooctaose and glycosides thereof, all of which may be optionally substituted with one or more sialic acid and / or fucose residues. The preferred compounds of formula 1b prepared by the present method are selected from lacto-N-tetraose, lacto-N-hexaose, lacto-N-octaose, iso-lactose-N-octaose, lacto-N-decasose, lacto-N-undecasose and glycosides thereof, all of which may be optionally substituted with one or more sialic acid residues and / or fucose residues.
[0108] Particularly preferred compounds of the formula 1a or 1b are characterized in that:
[0109] - a fucose residue linked to an N-acetyl-lactosamine group and / or a lacto-N-biosyl group
[0110] Galactose having 1 to 2 lacto-N-biose groups with internal glycosidic bonds, and / or
[0111] N-acetyl-glucosamine having 1 to 4 lacto-N-biosyl groups with internal glycosidic bonds, and / or
[0112] N-acetyl-glucosamine having 1 to 3 N-acetyl-lactosaminoglycan groups with internal glycosidic bonds,
[0113] - Sialic acid residues linked to N-acetyl-lactosamine and / or lacto-N-biosyl groups
[0114] Galactose having 2 to 3 lacto-N-biosyl groups with internal glycosidic bonds, and / or
[0115] N-acetyl-glucosamine having 2 to 6 lacto-N-biosyl groups with internal glycosidic bonds, and / or
[0116] Galactose having 2 to 6 N-acetyl-lactosaminoglycans with internal glycosidic bonds.
[0117] According to the most preferred aspect, the compound of formula 1a, 1b or 1c is selected from 2'-fucosyllactose, 3-fucosyllactose, 2',3-difucosyllactose, 3'-sialyl lactose, 6'-sialyl lactose, 3'-sialyl-3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LST-a, LST-b, LST-c, FLST-a, FLST-b, FLST-c, LNDFH-I, LNDFH-II, LNDFH-III, DS-LNT, FDS-LNT I, FDS-LNT II and glycosides thereof, or salts thereof. The glycoside may be α- or β-anomer, but is preferably β-anomer.
[0118] The preferred exogenous carbohydrate acceptor added to the culture medium is lactic acid, and the preferred oligosaccharide product is human milk oligosaccharide (HMO). HMO consists of a lactose unit at the reducing end and one or more monosaccharide units from the following: N-acetyl-glucosamine, galactose, fucose and sialic acid (see: Milk Oligosaccharides by Urashima et al., Nova Biomedical Books, New York, 2011, ISBN: 978-1-61122-831-1). Then, to prepare HMOs, the cells comprise one or more recombinant genes encoding β-1,3-N-acetyl-glucosaminyltransferase, β-1,6-N-acetyl-glucosaminyltransferase, β-1,3-galactosyltransferase, β-1,4-galactosyltransferase, α-2,3-sialyltransferase, α-2,6-sialyltransferase, α-1,2-fucosyltransferase, α-1,3-fucosyltransferase and / or α-1,4-fucosyltransferase, and further comprise a biosynthetic pathway to the corresponding activated sugar nucleotides, i.e., UDP-GlcNAc, UDP-Gal, GDP-Fuc and / or CMP-sialic acid.
[0119] According to another preferred embodiment, the method for preparing N-acetylated HMO, preferably N-acetylated HMO with 3 to 5 monosaccharide units, comprises the following steps:
[0120] (i) Provide LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - A transgenic Escherichia coli cell of a genotype comprising:
[0121] - a recombinant gene encoding an N-acetyl-glucosaminyltransferase capable of transferring the GlcNAc of UDP-GlcNAc to internalized lactose,
[0122] - optionally a recombinant gene encoding a galactosyltransferase capable of transferring the galactose residue of UDP-Gal to N-acetyl-glucosaminylated lactose, and
[0123] - one or more genes encoding the biosynthetic pathway leading to UDP-GlcNAc and optionally UDP-Gal,
[0124] (ii) In the presence of exogenous lactose and sucrose, LacZ - , LacY + Genotype or LacZ - , LacY+ 、Lacl - The transgenic E. coli cells of the same genotype were cultured to induce:
[0125] - internalization of exogenous lactose by the cell via an active transport mechanism, and
[0126] - Formation of N-acetyl-glucosaminylated lactose, optionally galactosylated, within the cell, followed by
[0127] (iii) separating the optionally galactosylated N-acetyl-glucosaminylated lactose from the cells, from the culture medium or from both,
[0128] Characterized in that the cell further comprises a heterologous PTS-dependent sucrose utilization system to provide sucrose as a carbon source and energy source for the biosynthesis of UDP-GlcNAc and optionally UDP-Gal by the cell.
[0129] The heterologous PTS-dependent sucrose utilization system preferably includes scr genes, more preferably includes scrY, scrA, scrB and scrR, and especially does not include scrK.
[0130] If the N-acetyl-glucosaminyltransferase is β-1,3-N-acetyl-glucosaminyltransferase and a recombinant gene encoding a galactosyltransferase is not present in the cell, the product is preferably lacto-N-triose, and if β-1,3-galactosyltransferase or β-1,4-galactosyltransferase is also present in the cell, the product is preferably LNT or LNnT, respectively.
[0131] According to another preferred embodiment, the method of the present invention for preparing fucosylated HMO, preferably fucosylated HMO with 3 to 5 monosaccharide units, comprises the following steps:
[0132] (i) Provide LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - A transgenic Escherichia coli cell of a genotype comprising:
[0133] - a recombinant gene encoding a fucosyltransferase capable of transferring the fucose residue of GDP-Fuc to internalized lactose, and
[0134] - one or more genes encoding a biosynthetic pathway leading to GDP-Fuc,
[0135] (ii) culturing the cells in the presence of exogenous lactose and sucrose to induce:
[0136] - internalization of exogenous lactose by the transgenic cells via an active transport mechanism, and
[0137] - Formation of fucosylated lactose, then
[0138] (iii) separating fucosylated lactose from the cells, from the culture medium or from both,
[0139] Characterized in that the cell also comprises a heterologous PTS-dependent sucrose utilization system to provide sucrose as a carbon source and an energy source for the biosynthesis of GDP-Fuc by the cell. Preferably, in the method, the culturing step comprises two-step feeding, and the second feeding stage is to slow down the cell growth and increase the content of the product prepared in the high cell concentration culture by continuously adding less sucrose to the culture than the amount continuously added in the first feeding stage. During the second feeding stage, the feed rate of sucrose continuously added to the cell culture is about 30-40% less than the sucrose continuously added during the first feeding stage. During the two feeding stages, lactose can be added continuously, preferably in the same feeding solution as sucrose, or lactose and sucrose are added sequentially. Optionally, when a considerable amount of unused receptors remain in the extracellular part after the second stage, the culture further comprises a third feeding stage. Then, preferably at approximately the same feed rate as set for the second feeding stage, sucrose is continued to be added without adding receptors until the receptors are consumed.
[0140] The heterologous PTS-dependent sucrose utilization system preferably comprises scr genes, more preferably scrY, scrA, scrB and scrR, and especially excludes scrK.
[0141] If the fucosyltransferase is an α-1,2-fucosyltransferase, the product is preferably 2'-fucosyllactose, if the fucosyltransferase is an α-1,3-fucosyltransferase, the product is preferably 3-fucosyllactose, if both α-1,2-fucosyltransferase and α-1,3-fucosyltransferase are expressed in the cell, the product is preferably difucosyllactose.
[0142] According to still another preferred embodiment, the method of the present invention for preparing sialylated HMO, preferably sialylated HMO with 3 to 5 monosaccharide units, comprises the following steps:
[0143] (i) Provide LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - A transgenic Escherichia coli cell of a genotype comprising:
[0144] - a recombinant gene encoding a sialyltransferase capable of transferring the sialic acid residue of CMP-sialic acid to internalized lactose, and
[0145] - one or more genes encoding the biosynthetic pathway leading to CMP-sialic acid,
[0146] (ii) In the presence of exogenous lactose and sucrose, LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - The transgenic E. coli cells of the same genotype were cultured to induce:
[0147] - internalization of exogenous lactose by the transgenic cells via an active transport mechanism, and
[0148] - Formation of sialylated lactose, then
[0149] (iii) separating sialylated lactose from the cells, from the culture medium or from both,
[0150] Characterized in that the cell further comprises a heterologous PTS-dependent sucrose utilization system to provide sucrose as a carbon source and energy source for the biosynthesis of CMP-sialic acid by the cell.
[0151] The heterologous PTS-dependent sucrose utilization system preferably includes scr genes, more preferably includes scrY, scrA, scrB and scrR, and especially does not include scrK.
[0152] If the sialyltransferase is an α-2,3-sialyltransferase, the product is preferably 3'-sialyl lactose, and if the sialyltransferase is an α-2,6-sialyltransferase, the product is preferably 6'-sialyl lactose.
[0153] According to another preferred embodiment, the method of the present invention for preparing fucosylated and sialylated HMO, preferably fucosylated and sialylated HMO of 3 to 5 monosaccharide units, comprises the following steps:
[0154] (i) Provide LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - A transgenic Escherichia coli cell of a genotype comprising:
[0155] - a recombinant gene encoding a sialyltransferase capable of transferring the sialic acid residue of CMP-sialic acid to internalized lactose or to previously fucosylated lactose,
[0156] - a recombinant gene encoding a fucosyltransferase capable of transferring the fucose residue of GDP-Fuc to internalized lactose or to previously sialylated lactose, and
[0157] - one or more genes encoding the biosynthetic pathways leading to CMP-sialic acid and GDP-Fuc,
[0158] (ii) In the presence of exogenous lactose and sucrose, LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - The transgenic E. coli cells of the same genotype were cultured to induce:
[0159] - internalization of exogenous lactose by the transgenic cells via an active transport mechanism, and
[0160] - formation of sialyl-fucosyl-lactose, then
[0161] (iii) isolating sialyl-fucosyl-lactose from the cells, from the culture medium, or from both,
[0162] Characterized in that the cell further comprises a heterologous PTS-dependent sucrose utilization system to provide sucrose as a carbon source and energy source for the biosynthesis of CMP-sialic acid and GDP-Fuc by the cell.
[0163] The heterologous PTS-dependent sucrose utilization system preferably includes scr genes, more preferably includes scrY, scrA, scrB and scrR, and especially does not include scrK.
[0164] If the sialyltransferase is an α-2,3-sialyltransferase and the fucosyltransferase is an α-1,3-fucosyltransferase, the product is preferably 3'-sialyl-3-fucosyllactose.
[0165] A second aspect of the present invention is to provide a transgenic microorganism capable of internalizing sucrose and a carbohydrate receptor other than sucrose, preferably lactose, into the microorganism, and comprising:
[0166] - a recombinant gene encoding a glycosyltransferase capable of transferring the sugar residue of an activated sugar nucleotide to an acceptor in a microorganism,
[0167] - a biosynthetic pathway for the preparation of activated sugar nucleotides from sucrose, and
[0168] - one or more genes encoding a heterologous PTS-dependent sucrose utilization system, preferably a scr gene, whereby the cell is able to use sucrose as a carbon source, preferably as the main carbon source, more preferably as the sole carbon source, for the preparation of the activated sugar nucleotides, and as an energy source, preferably as the main energy source, more preferably as the sole energy source, for the preparation of the oligosaccharides.
[0169] The transgenic microorganism of the second aspect is selected from bacteria and yeast, preferably bacteria. The bacteria are preferably selected from the following: Escherichia coli, Bacillus spp. (e.g. Bacillus subtilis), Campylobacter pylori, Helicobacter pylori, Agrobacterium tumefaciens, Staphylococcus aureus, Thermophilus aquaticus, Azorhizobium caulinodans, Rhizobium leguminosarum, Neisseria gonorrhoeae, Neisseria meningitis, Lactobacillus spp., Lactococcus spp., Enterococcus spp.), Bifidobacterium spp., Sporolactobacillus spp., Micromomospora spp., Micrococcus spp., Rhodococcus spp., and Pseudomonas, among which Escherichia coli is preferred.
[0170] Furthermore, the transgenic cell of the second aspect comprises one or more endogenous or recombinant genes encoding one or more glycosyltransferases capable of transferring the sugar residue of an activated sugar nucleotide to an internalized acceptor. The source of the heterologous nucleic acid sequence can be any animal (including human) or plant, eukaryotic cells such as those from Saccharomyces cerevisae, Saccharomyces pombe, Candida albican or those from algae, prokaryotic cells such as those from Escherichia coli, Bacterioides fragilis, Photobacterium sp., Bacillus subtilis, Campylobacter pylori, Helicobacter pylori, Agrobacterium tumefaciens, Staphylococcus aureus, Thermophilus aquaticus, Azorhizobium caulinodans, Rhizobium leguminosarum, leguminosarum), Rhizobium meliloti, Neisseria gonorrhoeae and Neisseria meningitidis, or viruses. The glycosyltransferase or the enzyme expressed by the protein encoded by the gene or equivalent DNA sequence is preferably a glucosyltransferase, a galactosyltransferase, an N-acetylglucosaminyltransferase, an N-acetylgalactosamine transferase, a glucuronyltransferase, a xylosyltransferase, a mannosyltransferase, a fucosyltransferase, a sialyltransferase, and the like. In a preferred embodiment, the glycosyltransferase is selected from the group consisting of β-1,3-N-acetylglucosamine-transferase, β-1,6-N-acetylglucosamine-transferase, β-1,3-galactosyl-transferase, β-1,4-galactosyl-transferase, β-1,3-N-acetylgalactosamine-transferase, β-1,3-glucuronyl-transferase, α-2,3-sialyl-transferase, α-2,6-sialyl-transferase, α-2,8-sialyl-transferase, α-1,2-fucosyl-transferase, α-1,3-fucosyl-transferase and α-1,4-fucosyl-transferase.More preferably, the glycosyltransferase is selected from the group consisting of β-1,3-N-acetylglucosaminyltransferase, β-1,6-N-acetylglucosaminyltransferase, β-1,3-galactosyltransferase, β-1,4-galactosyltransferase, α-2,3-sialyltransferase, α-2,6-sialyltransferase, α-1,2-fucosyltransferase, α-1,3-fucosyltransferase and α-1,4-fucosyltransferase, from those enzymes involved in building the HMO core structure and fucosylated and / or sialylated HMOs and glycosyl derivatives thereof, wherein the aglycone is the moiety defined at the group of the carbohydrate acceptor above.
[0171] Then, the transgenic microorganism of the second aspect of the present invention comprises a transport system that internalizes an exogenous carbohydrate receptor, preferably lactic acid, into a microorganism for glycosylation to prepare a heterologous oligosaccharide of interest, preferably an oligosaccharide that does not adversely affect the basic functions of the cell or destroy its integrity. Preferably, the carbohydrate is internalized with the help of active transport mediated by a transporter protein, a so-called permease, which acts as an enzyme, and whereby the microorganism can allow exogenous substances to enter and concentrate them in the cytoplasm. In particular, lactose permease (LacY) specifically acts on galactose, simple galactosyl disaccharides such as lactose and its glycosides. The transgenic microorganism preferably lacks any enzymatic activity (such as LacZ) that may degrade the receptor. Similarly, the microorganism cannot hydrolyze or degrade the oligosaccharide product.
[0172] In addition, the transgenic microorganism of the second aspect comprises a gene encoding a phosphoenolpyruvate (PEP)-dependent phosphotransferase (PTS) sucrose utilization system, i.e., the cell has the ability to utilize sucrose catabolism as a carbon and energy source. The PTS system is heterologous (i.e., derived from a different organism and transferred to a host cell by conventional recombinant DNA manipulation techniques, preferably via an expression vector), and is encoded by a scr or sac gene, preferably a scr gene.
[0173] Preferably, the scr genes contained by the transgenic microorganism, preferably Escherichia coli, are the following: scrY, scrA, scrB and scrR. scrA gene encodes sucrose transporter II Scr, which provides intracellular sucrose-6-phosphate from the extracellular sucrose and accompanying phosphorylation through the cell membrane via active transport. The sucrose-specific ScrY membrane pore protein (encoded by scrY) promotes the diffusion of sucrose through the outer membrane. The ScrB invertase (encoded by scrB) decomposes the accumulated sucrose-6-phosphate into glucose-6-phosphate and fructose by hydrolysis. The presence of fructokinase ScrK (encoded by scrK) is not critical because fructose can be phosphorylated by other mechanisms possessed by the cell. The repressor protein ScrR (encoded by scrR) negatively controls the expression of the scrYAB gene, and ScrR is induced by sucrose or fructose.
[0174] In a preferred embodiment, the heterologous scr gene is introduced into the microorganism using a plasmid, more preferably a two-plasmid system, one of which contains the scrA gene and the other contains the scrB gene. The scrY and scrR genes can be carried by either plasmid.
[0175] Preferably, the transgenic microorganism of the second aspect has a deleted or deficient lacA gene on the lac operon.
[0176] It is also preferred that the lac1 gene of the lac repressor is also deleted in the transgenic microorganism.
[0177] The genetically modified microorganism disclosed above is suitable for preparing the oligosaccharide of formula 1 from lactose or lactoside having the above-mentioned aglycone
[0178]
[0179] wherein Y is OH or a non-aglycone as defined above, preferably OH,
[0180] R1 is fucosyl or H,
[0181] R2 is fucosyl or H,
[0182] R3 is selected from H, sialic acid, N-acetyl-lactosamino and lacto-N-biosyl groups, wherein the N-acetyl-lactosamino group may carry a sugar residue comprising one or more N-acetyl-lactosamino groups and / or one or more lacto-N-biosyl groups; each N-acetyl-lactosamino and lacto-N-biosyl group may be substituted by one or more sialic acid residues and / or fucose residues,
[0183] R4 is selected from H, sialic acid and N-acetyl-lactosamino groups, the N-acetyl-lactosamino groups being optionally substituted by sugar residues comprising one or more N-acetyl-lactosamino groups and / or one or more lacto-N-biosyl groups; each N-acetyl-lactosamino and lacto-N-biosyl group being capable of being substituted by one or more sialic acid residues and / or fucose residues,
[0184] The proviso is that at least one of the R1, R2, R3 and R4 groups is different from H.
[0185] Preferably, the oligosaccharide of Formula 1 is a human milk oligosaccharide (when Y is OH) or a glycoside thereof (when Y is a non-aglycone), more preferably a human milk oligosaccharide.
[0186] According to a preferred embodiment, the transgenic microorganism is LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - An Escherichia coli cell of the genotype comprising:
[0187] - a recombinant gene encoding an N-acetyl-glucosaminyltransferase capable of transferring the GlcNAc of UDP-GlcNAc to internalized lactose,
[0188] - optionally a recombinant gene encoding a galactosyltransferase capable of transferring the galactose residue of UDP-Gal to N-acetyl-glucosaminylated lactose,
[0189] - one or more genes encoding the biosynthetic pathway to UDP-GlcNAc and optionally UDP-Gal, and
[0190] - A heterologous PTS-dependent sucrose utilization system comprising scrY, scrA, scrB and scrR genes to provide a carbon source as well as an energy source for the biosynthesis of UDP-GlcNAc and optionally UDP-Gal produced by the cell.
[0191] In particular, the heterologous scr cluster does not include scrK.
[0192] More preferably, the N-acetyl-glucosaminyltransferase is β-1,3-N-acetylglucosaminyltransferase, and the gene encoding galactosyltransferase is absent in the cell. In this case, the transgenic E. coli mainly produces lacto-N-triose.
[0193] Furthermore, it is more preferred that the N-acetyl-glucosaminyltransferase is β-1,3-N-acetylglucosaminyltransferase, and the galactosyltransferase is β-1,3-galactosyltransferase. In this case, the transgenic E. coli mainly produces LNT.
[0194] Still more preferably, the N-acetyl-glucosaminyltransferase is β-1,3-N-acetylglucosaminyltransferase, and the galactosyltransferase is β-1,4-galactosyltransferase. In this case, the transgenic E. coli mainly produces LNnT.
[0195] According to another preferred embodiment, the transgenic microorganism is LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - An Escherichia coli cell of the genotype comprising:
[0196] - a recombinant gene encoding a sialyltransferase capable of transferring the fucose residue of GDP-Fuc to internalized lactose, and
[0197] - one or more genes encoding a biosynthetic pathway leading to GDP-Fuc,
[0198] - A heterologous PTS-dependent sucrose utilization system comprising scrY, scrA, scrB and scrR to provide sucrose as a carbon source as well as an energy source for the biosynthesis of GDP-Fuc by the cell.
[0199] In particular, the heterologous scr cluster does not include scrK.
[0200] More preferably, the fucosyltransferase is α-1,2-fucosyltransferase. In this case, the transgenic E. coli mainly produces 2'-FL.
[0201] It is also more preferred that the fucosyltransferase is α-1,3-fucosyltransferase. In this case, the transgenic E. coli mainly produces 3'-FL.
[0202] Still more preferably, two fucosyltransferases are present in the cells: α-1,2-fucosyltransferase and α-1,3-fucosyltransferase. In this case, the transgenic E. coli mainly produces DFL.
[0203] According to another preferred embodiment, the transgenic microorganism is LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - An Escherichia coli cell of the genotype comprising:
[0204] - a recombinant gene encoding a sialyltransferase capable of transferring the sialic acid residue of CMP-sialic acid to internalized lactose,
[0205] - one or more genes encoding the biosynthetic pathway leading to CMP-sialic acid, and
[0206] - A heterologous PTS-dependent sucrose utilization system comprising scrY, scrA, scrB and scrR to provide sucrose as a carbon source as well as an energy source for the biosynthesis of CMP-sialic acid produced by the cell.
[0207] In particular, the heterologous scr cluster does not include scrK.
[0208] More preferably, the sialyltransferase is α-2,3-sialyltransferase. In this case, the transgenic E. coli mainly produces 3'-SL.
[0209] It is also more preferred that the sialyltransferase is α-2,6-sialyltransferase. In this case, the transgenic E. coli mainly produces 6'-SL.
[0210] According to another preferred embodiment, the transgenic microorganism is LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - An Escherichia coli cell of the genotype comprising:
[0211] a recombinant gene encoding a sialyltransferase capable of transferring the sialic acid residue of CMP-sialic acid to internalized lactose, which is optionally fucosylated,
[0212] - a recombinant gene encoding a fucosyltransferase capable of transferring the fucose residue of GDP-Fuc to internalized lactose, which is optionally sialylated,
[0213] - one or more genes encoding the biosynthetic pathway leading to CMP-sialic acid,
[0214] - one or more genes encoding the biosynthetic pathway leading to GDP-Fuc, and
[0215] - A heterologous PTS-dependent sucrose utilization system comprising scrY, scrA, scrB and scrR to provide sucrose as a carbon source as well as an energy source for the biosynthesis of CMP-sialic acid and GDP-Fuc produced by the cell.
[0216] In particular, the heterologous scr cluster does not include scrK.
[0217] More preferably, the sialyltransferase is α-2,3-sialyltransferase and the fucosyltransferase is α-1,3-fucosyltransferase. In this case, the transgenic E. coli mainly produces 3'-sialyl-3-fucosyllactose.
[0218] Example
[0219] Example 1: Comparative test of preparing LNnT from glycerol or sucrose using Escherichia coli
[0220] Bacterial strains:
[0221] Both strains were constructed from Escherichia coli K12 strain DH1 obtained from the Deutsche Sammlung von Mikroorganism (reference DSM 5346) by deleting the lacZ nanKETA lacA melA wcaJ mdoH genes and inserting the Plac promoter while retaining the genes involved in the biosynthesis of UDP-GlcNAc and UDP-Gal. The glycerol utilization strain (strain I) comprises a pBBR3-lgtA-tet plasmid and a pBS-galT-amp plasmid, wherein the pBBR3-lgtA-tet plasmid carries the lgtA gene of Neisseria meningitidis (N.Meningitidis) for β-1,3-N-acetylglucosaminyltransferase and a tetracycline resistance gene, and the pBS-galT-amp plasmid carries the galT gene of Helicobacter pylori for β-1,4-galactosyltransferase and an ampicillin resistance gene. The sucrose utilization strain (strain II) comprises the following two plasmids:
[0222] -pBS-scrBR-galT-amp, which is a pUC derivative carrying the galT gene encoding β-1,4-galactosyltransferase, the scrR gene encoding the sucrose repressor, the scrB gene encoding the sucrose-6-phosphate hydrolase, and the ampicillin resistance gene;
[0223] -pBBR3-scrYA-lgtA-tet, which is a pBBR1-MCS3 derivative carrying the lgtA gene encoding β-1,3-N-acetylglucosaminyltransferase, the scrA gene encoding the sucrose-specific EIIBC component of the PTS system, the scrY gene encoding the sucrose membrane porin, and a tetracycline resistance gene.
[0224] Fermentation steps:
[0225] Glucose, glycerol, sucrose, and lactose were each sterilized at 120° C. Isopropylmercapto β-D-galactoside (IPTG) was filter sterilized.
[0226] Cultivation was carried out in a 3-liter fermentor containing approximately 0.9 liters of mineral medium (J. Biotechnol. 72, 33 (1999) by Samain et al.; no antibiotics were included for the sucrose system). The temperature was maintained at 33° C. and the pH was adjusted to 6.8 with 28% NH4OH. An inoculum of the production strain included in LB medium (20 ml) or M9 medium (20 ml) was added to the fermentor, the LB medium being used for strain I and supplemented with ampicillin and tetracycline, or the M9 medium being used for strain II and supplemented with sucrose. The exponential growth phase began with inoculation and ended until the carbon source initially added to the culture medium (glucose for strain I or sucrose for strain II, ≈17.5 g / l) was exhausted. A lactose solution (70 g lactose / 500 ml water) was then added before starting feeding with a carbon source (500 g / l solution, 4.5 g / h glycerol for strain I, 3 g / l sucrose for strain II). Inducer (isopropylmercapto-β-D-galactoside, IPTG, 1-2 ml of a 50 mg / ml solution) was also added. The glycerol-fed fermentation (strain I) continued for 90 hours after cell death (LNnT titer: 45 g / l). The sucrose-fed fermentation (strain II) produced a LNnT concentration of 56 g / l after 116 hours.
[0227] Example 2: Preparation of 2'-FL from sucrose using E. coli
[0228] Bacterial strains:
[0229] Both strains were constructed from Escherichia coli K12 strain DH1 by deleting the lacZ nanKETA lacA melA wcaJ mdoH genes and inserting the Plac promoter upstream of the gmd gene, obtained from the Deutsche Sammlung von Mikroorganism (reference DSM5346). In addition, the strain contained the following two plasmids:
[0230] -pBS-futC-scrBR-amp, which is a pUC derivative carrying the futC gene encoding α-1,2-fucosyltransferase, the scrR gene encoding the sucrose repressor, the scrB gene encoding the sucrose-6-phosphate hydrolase, and the ampicillin resistance gene;
[0231] -pBBR3-GMAB-scrYA-tet, which is a pBBR1-MCS3 derivative carrying the manB, manC, gmd and wcaG genes involved in GDP-Fuc biosynthesis, the scrA gene encoding the sucrose-specific EIIBC component of the PTS system, the scrY gene encoding the sucrose membrane porin, and the tetracycline resistance gene.
[0232] Fermentation steps:
[0233] Sucrose and lactose were each sterilized at 120° C. Isopropylmercapto β-D-galactoside (IPTG) was filter sterilized.
[0234] Cultivation was carried out in a 2-liter fermentor containing approximately 0.9 liters of mineral medium (Samain et al. J. Biotechnol. 72, 33 (1999); antibiotics were not included). The temperature was maintained at 33° C. and the pH was adjusted to 6.8 with 28% NH4OH. An inoculum of the production strain in M9 medium (20 ml) supplemented with sucrose was added to the fermentor. The exponential growth phase began with the inoculation and ended with the exhaustion of the sucrose (≈22 g / l) initially added to the medium. The inducer (isopropylmercapto-β-D-galactoside, IPTG, 1-2 ml of a 50 mg / ml solution) was then added. Feeding with lactose + sucrose (160 g lactose + 500 g sucrose per liter of water) was started at a rate of 9 ml / h for 6 hours and then continued at a rate of 6 ml / h for 115 hours. The concentration of 2'-FL in the supernatant at the end of the fermentation was approximately 100 g / l.
Claims
1. A method for preparing a recombinant oligosaccharide by glycosylation of a carbohydrate receptor, wherein the receptor is lactose, wherein the recombinant oligosaccharide is 2'-FL, the method comprising the following steps: a) providing an E. coli cell, which is capable of internalizing the receptor into the cell and which comprises: - a recombinant gene encoding a glycosyltransferase capable of transferring a sugar residue of an activated sugar nucleotide to a receptor internalized in said cell, and - a biosynthetic pathway for producing said activated sugar nucleotide in said cell, b) culturing the cell in the presence of the receptor and sucrose, and c) isolating the oligosaccharide from the cell, the culture medium or both, The method is characterized in that the cell further comprises one or more genes encoding a heterologous PTS-dependent sucrose utilization transport system, whereby the cell is able to use sucrose as a carbon source for producing the activated sugar nucleotides and as an energy source for producing the oligosaccharides, and wherein the activated sugar nucleotide is GDP-Fuc, wherein the glycosyltransferase is an α-1,2-fucosyltransferase, which is capable of transferring the fucose residue of GDP-Fuc to the internalized lactose to form 2'-FL, and The heterologous PTS-dependent sucrose utilization transport system comprises scr genes, which include scrY for sucrose membrane porin, scrA for PTS permease, scrB for sucrose-6-phosphate hydrolase, scrR for repressor protein, and optionally scrK for fructokinase.
2. The method of claim 1, wherein the scr gene is on two plasmids in the cell.
3. The method according to claim 2, wherein of the two plasmids, one plasmid carries scrA and the other plasmid carries scrB.
4. The method according to any one of claims 1 to 3, wherein the cell comprises one or more lac genes lacking lacZ and lacA.
5. The method of claim 4, wherein the cells comprise a deleted lac1 gene.
6. The method according to any one of claims 1 to 3, comprising the following steps: ⅰ) Provide LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - Genotype of transgenic E. coli cells, (ii) culturing the cell in a fermentation broth comprising lactose and sucrose, thereby inducing: - internalizing said lactose into said cell via an active transport mechanism, and - formation of 2'-FL, and (iii) isolating 2'-FL from the cells, the culture medium, or both.
7. A transgenic microorganism for preparing a recombinant oligosaccharide, wherein the recombinant oligosaccharide is 2'-FL, and the microorganism is Escherichia coli, comprising: - a recombinant gene encoding a glycosyltransferase capable of transferring a sugar residue of an activated sugar nucleotide to a carbohydrate acceptor, said acceptor being lactose, said acceptor being internalized by the microorganism, - a biosynthetic pathway for preparing said activated sugar nucleotides from sucrose, and - one or more genes encoding a heterologous PTS-dependent sucrose utilization system, the scr gene, whereby the cell is able to use sucrose as a carbon source for the preparation of the activated sugar nucleotides, and as an energy source, and wherein the activated sugar nucleotide is GDP-Fuc, wherein the glycosyltransferase is an α-1,2-fucosyltransferase, which is capable of transferring the fucose residue of GDP-Fuc to the internalized lactose to form 2'-FL, and The scr genes include scrY of sucrose membrane porin, scrA of PTS permease, scrB of sucrose-6-phosphate hydrolase and scrR of repressor protein.
8. The transgenic microorganism of claim 7, wherein the scr gene is on two plasmids in the cell.
9. The transgenic microorganism according to claim 8, wherein of the two plasmids, one plasmid carries scrA and the other plasmid carries scrB.
10. The transgenic microorganism according to any one of claims 7 to 9, comprising one or more lac genes lacking lacZ and lacA.
11. The transgenic microorganism according to claim 10, comprising a deleted lacl.
12. The transgenic microorganism according to any one of claims 7 to 9, which is LacZ - , LacY + Genotype or LacZ - , LacY + 、Lacl - Genotypes of E. coli cells.
Citation Information
Patent Citations
Method of producing 6-thio-sialylated glycoproteins and glycoconjugates
EP1911850A1
Method for producing oligopolysaccharides
WO2001004341A1
Glycoproteins and glycosylated cells and a method for the preparation of the same
WO2009040363A1
Recombinant bacteria having the ability to metabolize sucrose
WO2012078311A1
Method for producing oligosaccharides and oligosaccharide glycosides by fermentation
WO2013182206A1
